- Home
- WY vs BIIB Comparison
WY vs BIIB Comparison
Compare WY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WY
- BIIB
- Stock Information
- Founded
- WY 1900
- BIIB 1978
- Country
- WY United States
- BIIB United States
- Employees
- WY N/A
- BIIB N/A
- Industry
- WY Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WY Real Estate
- BIIB Health Care
- Exchange
- WY Nasdaq
- BIIB Nasdaq
- Market Cap
- WY 22.5B
- BIIB 25.1B
- IPO Year
- WY N/A
- BIIB 1991
- Fundamental
- Price
- WY $28.26
- BIIB $149.02
- Analyst Decision
- WY Buy
- BIIB Buy
- Analyst Count
- WY 7
- BIIB 26
- Target Price
- WY $35.71
- BIIB $248.00
- AVG Volume (30 Days)
- WY 3.6M
- BIIB 1.6M
- Earning Date
- WY 01-30-2025
- BIIB 02-11-2025
- Dividend Yield
- WY 2.83%
- BIIB N/A
- EPS Growth
- WY N/A
- BIIB 10.05
- EPS
- WY 0.73
- BIIB 11.06
- Revenue
- WY $7,190,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- WY N/A
- BIIB N/A
- Revenue Next Year
- WY $8.11
- BIIB N/A
- P/E Ratio
- WY $38.69
- BIIB $13.47
- Revenue Growth
- WY N/A
- BIIB N/A
- 52 Week Low
- WY $26.73
- BIIB $145.07
- 52 Week High
- WY $36.27
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- WY 34.20
- BIIB 32.44
- Support Level
- WY $27.18
- BIIB $145.07
- Resistance Level
- WY $31.93
- BIIB $149.92
- Average True Range (ATR)
- WY 0.77
- BIIB 3.81
- MACD
- WY -0.29
- BIIB 0.05
- Stochastic Oscillator
- WY 19.57
- BIIB 22.51
About WY Weyerhaeuser Company
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.